James F. Howard, Jr., MD, FAAN, University of North Carolina School of Medicine, Chapel Hill, NC, shares insights into knowledge gaps and questions that need to be addressed to optimize the management of myasthenia gravis. More research is required in order to better understand the role and safety of complement inhibitors in seronegative patients, in children, and during pregnancy. Prof. Howard further highlights the need to conduct more studies and obtain real-world data. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.
Disclosures
Research support paid to institution: Alexion Pharmaceuticals, Argenx BVBA, Cartesian Therapeutics, The Centers for Disease Control and Prevention, Millennium/Takeda Pharmaceuticals, National Institutes of Health, PCORI, Ra Pharmaceuticals (now UCB)
Honoraria: Alexion Pharmaceuticals, Argenx BVBA, Ra Pharmaceuticals (now UCB), Immunovant, Regeneron Pharmaceuticals, Sanofi US, Toleranzia AB, Viela Bio Inc (now Horizon Therapeutics)
Stock dividends: Johnson & Johnson, Pfizer, General Electric, GlaxoSmithKline
